Aronora is a translational biotechnology company focused on the early-stage commercial development of proprietary biologic therapeutics, including recombinant monoclonal antibodies and enzymes. Their drug products aim to reduce the progression and growth of life-threatening blood clots without the detrimental bleeding side effects of currently marketed antithrombotic drugs. The company's innovative therapeutic agents are designed to be used in severe, rapidly progressing, or catastrophic thrombotic blood clotting diseases, where there are currently limited treatment options available. By providing better medications to treat clots, Aronora aims to improve healthcare providers' access to effective and safe therapies.